X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES BIOCON LTD JUBILANT LIFE SCIENCES/
BIOCON LTD
 
P/E (TTM) x 26.3 84.6 31.1% View Chart
P/BV x 5.4 8.0 67.9% View Chart
Dividend Yield % 0.3 0.2 216.0%  

Financials

 JUBILANT LIFE SCIENCES   BIOCON LTD
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
BIOCON LTD
Mar-17
JUBILANT LIFE SCIENCES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1871,162 16.1%   
Low Rs65483 13.5%   
Sales per share (Unadj.) Rs364.3194.6 187.3%  
Earnings per share (Unadj.) Rs6.834.4 19.9%  
Cash flow per share (Unadj.) Rs24.548.3 50.8%  
Dividends per share (Unadj.) Rs3.001.00 300.0%  
Dividend yield (eoy) %2.40.1 1,958.4%  
Book value per share (Unadj.) Rs164.9241.9 68.2%  
Shares outstanding (eoy) m159.28200.00 79.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.2 8.2%   
Avg P/E ratio x18.423.9 77.0%  
P/CF ratio (eoy) x5.117.0 30.2%  
Price / Book Value ratio x0.83.4 22.5%  
Dividend payout %43.82.9 1,507.7%   
Avg Mkt Cap Rs m20,061164,440 12.2%   
No. of employees `0006.29.2 67.0%   
Total wages/salary Rs m11,0527,470 147.9%   
Avg. sales/employee Rs Th9,383.04,213.9 222.7%   
Avg. wages/employee Rs Th1,786.9809.0 220.9%   
Avg. net profit/employee Rs Th176.3745.2 23.7%   
INCOME DATA
Net Sales Rs m58,03438,911 149.1%  
Other income Rs m1911,571 12.1%   
Total revenues Rs m58,22440,482 143.8%   
Gross profit Rs m5,7869,795 59.1%  
Depreciation Rs m2,8122,772 101.4%   
Interest Rs m3,237260 1,245.1%   
Profit before tax Rs m-728,334 -0.9%   
Minority Interest Rs m-286163 -175.5%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,616 43.1%   
Profit after tax Rs m1,0906,881 15.8%  
Gross profit margin %10.025.2 39.6%  
Effective tax rate %-965.919.4 -4,981.2%   
Net profit margin %1.917.7 10.6%  
BALANCE SHEET DATA
Current assets Rs m29,28040,477 72.3%   
Current liabilities Rs m38,91216,783 231.9%   
Net working cap to sales %-16.660.9 -27.3%  
Current ratio x0.82.4 31.2%  
Inventory Days Days8460 141.6%  
Debtors Days Days5183 61.2%  
Net fixed assets Rs m55,71245,073 123.6%   
Share capital Rs m1551,000 15.5%   
"Free" reserves Rs m20,96847,377 44.3%   
Net worth Rs m26,26548,377 54.3%   
Long term debt Rs m17,16921,082 81.4%   
Total assets Rs m88,60693,942 94.3%  
Interest coverage x1.033.1 3.0%   
Debt to equity ratio x0.70.4 150.0%  
Sales to assets ratio x0.70.4 158.1%   
Return on assets %4.97.6 64.3%  
Return on equity %4.214.2 29.2%  
Return on capital %11.612.6 91.7%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00412,988 169.4%   
Fx outflow Rs m11,7497,899 148.7%   
Net fx Rs m10,2555,089 201.5%   
CASH FLOW
From Operations Rs m8,0266,400 125.4%  
From Investments Rs m-1,744-4,985 35.0%  
From Financial Activity Rs m-4,447-1,775 250.6%  
Net Cashflow Rs m1,834-473 -387.8%  

Share Holding

Indian Promoters % 45.6 40.4 112.9%  
Foreign collaborators % 3.5 20.6 17.0%  
Indian inst/Mut Fund % 8.7 8.4 103.6%  
FIIs % 21.2 10.7 198.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 19.9 106.0%  
Shareholders   23,815 109,995 21.7%  
Pledged promoter(s) holding % 15.9 0.0 39,625.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Biocon: A Good Quarter (Quarterly Results Update - Detailed)

May 10, 2016

Biocon has announced its 4QFY16 and full year results. The company has reported 16.8% YoY growth in total income and 79.1% YoY increase in net profits. Here is our analysis of the results.

Biocon: Exceptional income saves the day (Quarterly Results Update - Detailed)

Jan 28, 2016

Biocon has announced its 2QFY16 results. The company has reported 10.5% YoY growth in total income and 199.9% YoY increase in net profits. Here is our analysis of the results.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jan 23, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - SHASUN PHARMA COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS